Greenwich LifeSciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	6.99	13.47	27.2	28.66	0.01	0.09
Cash & Cash Equivalents	6.99	13.47	27.2	28.66	0.01	0.09
Cash Growth	-48.10%	-50.49%	-5.08%	419217.85%	-91.97%	-
Other Current Assets	0.01	0.01	0.01	0.02	0	0
Total Current Assets	6.99	13.48	27.22	28.68	0.01	0.09
Goodwill and Intangibles	0.01	0.01	0.01	0.02	0.02	0.02
Other Long-Term Assets	-0.01	-0.01	-0.01	-0.02	0	0
Total Long-Term Assets	0	0	0	0	0.02	0.02
Total Assets	6.99	13.48	27.22	28.68	0.03	0.11
Accounts Payable	0.26	0.22	0.22	0.71	0.73	9.78
Current Debt	0	0	0	0.28	0.64	0.42
Other Current Liabilities	0.04	0.04	0.16	0.06	0.01	-9.47
Total Current Liabilities	0.29	0.26	0.39	1.05	1.38	0.73
Other Long-Term Liabilities	0	0	0	0	0	9.5
Total Long-Term Liabilities	0	0	0	0	0	9.5
Total Liabilities	0.29	0.26	0.39	1.05	1.38	10.23
Total Debt	0	0	0	0.28	0.64	0.42
Debt Growth	-	-	-	-56.68%	51.17%	-
Retained Earnings	-50.36	-41.47	-33.65	-29.08	-27.21	-23.79
Shareholders' Equity	6.7	13.21	26.83	27.63	-1.35	-10.12
Net Cash / Debt	6.99	13.47	27.2	28.39	-0.63	-0.34
Net Cash / Debt Growth	-48.10%	-50.49%	-4.16%	-	-	-
Net Cash Per Share	0.54	1.04	2.10	2.99	-0.28	-1.65
Working Capital	6.7	13.21	26.83	27.63	-1.37	-0.64
Book Value Per Share	0.52	1.02	2.07	2.91	-0.60	-49.85

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).